ArticlePloS one2026
Impact of blast exposure on visual pathway: Mechanism exploration and novel diagnostic perspectives.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blast-induced traumatic brain injury (bTBI), frequently observed in modern warfare, often presents without overt clinical symptoms initially, yet can involve visual impairment. However, the underlying mechanisms and long-term outcomes of visual dysfunction following blast exposure (BE) remain poorly understood. This study aimed to investigate the potential delayed effects of BE on visual function. A bTBI mouse model was established using a biological shock tube. Neurological deficits were assessed via the modified neurological severity score, while visual function was evaluated at multiple time points using flash visual evoked potentials (F-VEP) and a light-dark shuttle box. Ultrastructural evidence of damage was obtained through transmission electron microscopy (TEM). Inflammatory and pyroptosis markers were localized and quantified via immunofluorescence staining and Western blotting. Neuronal damage was detected by the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining combined with neuron-specific nuclear protein (NeuN) immunofluorescence labeling. To assess therapeutic potential, MCC950 was administered to bTBI mice, and visual function was re-evaluated. The results demonstrated that visual dysfunction emerged at 24 hours post BE, followed by a transient recovery, and reappeared at 28 days post BE. Early demyelination of the optic nerve and later pyroptosis of neurons in the visual cortex were identified as key pathological features. MCC950 treatment effectively mitigated neuroinflammation and neuronal pyroptosis, thereby ameliorating late-phase visual dysfunction. These findings collectively suggest that BE leads to biphasic visual dysfunction, driven by distinct mechanisms at different stages. Early intervention targeting nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome activation may represent a promising therapeutic strategy to prevent late-phase visual impairment. Moreover, non-invasive F-VEP provides a sensitive and practical approach for assessing visual injury in bTBI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.